刚果民主共和国孕妇及新生儿乙肝病毒母婴传播阻断可行性研究
在刚果民主共和国金沙萨两家产科中心,利用现有HIV母婴阻断平台对孕妇筛查乙肝,高风险者给予替诺福韦并给暴露婴儿接种出生剂乙肝疫苗。研究显示该策略可行且可接受,未观察到HBV母婴传播,无严重不良事件。
要点
- 将乙肝筛查和治疗纳入HIV母婴阻断平台在刚果民主共和国可行。
- 高病毒载量孕妇接受替诺福韦后病毒载量下降或抑制。
- 暴露婴儿出生剂疫苗接种率68%,及时接种率77%。
核心结论
- 在刚果民主共和国,将孕妇乙肝筛查、抗病毒治疗和婴儿出生剂疫苗接种整合到现有HIV母婴阻断平台是可行的。
研究设计与样本
- 在金沙萨Binza和Kingasani两家产科中心开展可行性研究,利用现有HIV母婴阻断项目筛查孕妇。
- 2018年9月24日至2019年2月22日共筛查4016名孕妇,109名HBsAg阳性,91名符合入选标准,90名纳入分析。
主要发现
- 88名暴露婴儿中60名(68%)接种出生剂疫苗,其中46名(77%)及时接种。
- 未观察到HBV母婴传播病例,未报告与替诺福韦或出生剂疫苗相关的严重不良事件;9名用药妇女中仅1名(11%)报告头晕。
- 母亲对研究程序的可接受性>80%。
关键数值与推荐
- 替诺福韦 disoproxil fumarate 300 mg/天,从妊娠28至32周开始,持续至产后12周。
临床怎么用
- 可利用现有HIV母婴阻断平台对孕妇进行乙肝筛查,识别高风险者并给予抗病毒 prophylaxis。
- 对HBV暴露婴儿应确保出生24小时内接种首剂乙肝疫苗。
- 将乙肝出生剂疫苗接种整合到扩大免疫规划和HIV母婴阻断项目中可能加速非洲乙肝消除。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite the widespread availability of effective childhood vaccines. In the Democratic Republic of the Congo, HBV treatment and birth-dose vaccination programmes are not established. We, therefore, aimed to evaluate the feasibility and acceptability of adding HBV testing and treatment of pregnant women as well as the birth-dose vaccination of HBV-exposed infants to the HIV prevention of mother-to-child transmission programme infrastructure in the Democratic Republic of the Congo. METHODS: We did a feasibility study in two maternity centres in Kinshasa: Binza and Kingasani. Using the already established HIV prevention of mother-to-child transmission programme at these two maternity centres, we screened pregnant women for HBV infection at routine prenatal care registration. Those who tested positive and had a gestational age of 24 weeks or less were included in this study. Eligible pregnant women with a high viral load (≥200 000 IU/mL or HBeAg positivity, or both) were considered as having HBV of high risk of mother-to-child transmission and initiated on oral tenofovir disoproxil fumarate (300 mg/day) between 28 weeks and 32 weeks of gestation and continued through 12 weeks post partum. All HBV-exposed infants received a birth-dose of monovalent HBV vaccine (Euvax-B Pediatric: Sanofi Pasteur, Seoul, South Korea; 0·5 mL) within 24 h of life. All women were followed up for 24 weeks post partum, when they completed an exit questionnaire that assessed the acceptability of study procedures. The primary outcomes were the feasibility of screening pregnant women to identify those at high risk for HBV mother-to-child transmission and to provide them with antiviral prophylaxis, the feasibility of administrating the birth-dose vaccine to exposed infants, and the acceptability of this prevention programme. This study is registered with ClinicalTrials.gov, NCT03567382. FINDINGS: Between Sept 24, 2018, and Feb 22, 2019, 4016 women were approached and screened. Of these pregnant women, 109 (2·7%) were positive for HBsAg. Of the 109 women, 91 (83%) met the eligibility criteria for participation. However, only data from 90 women-excluding one woman who had a false pregnancy-were included in the study analysis. The median overall age of the enrolled women was 31 years (IQR 25-34) and the median overall gestational age was 19 weeks (15-22). Ten (11%) of 91 women evaluated had high-risk HBV infection. Nine (90%) of the ten pregnant women with high-risk HBV infection received tenofovir disoproxil fumarate and one (10%) refused therapy and withdrew from the study; five (56%) of the nine women achieved viral suppression (ie, <200 000 IU/mL) on tenofovir disoproxil fumarate therapy by the time of delivery and the remaining four (44%) had decreased viral loads from enrolment to delivery. A total of 88 infants were born to the 90 enrolled women. Of the 88 infants, 60 (68%) received a birth-dose vaccine; of these, 46 (77%) received a timely birth-dose vaccine. No cases of HBV mother-to-child transmission were observed. No serious adverse events associated with tenofovir disoproxil fumarate nor with the birth-dose vaccine were reported. Only one (11%) of nine women reported dizziness during the course of tenofovir disoproxil fumarate therapy. The study procedures were considered highly acceptable (>80%) among mothers. INTERPRETATION: Adding HBV screening and treatment of pregnant women and infant birth-dose vaccination to existing HIV prevention of mother-to-child transmission platforms is feasible in countries such as the Democratic Republic of the Congo. Birth-dose vaccination against HBV infection integrated within the current Expanded Programme on Immunisation and HIV prevention of mother-to-child transmission programme could accelerate progress toward HBV elimination in Africa. FUNDING: Gillings Innovation Laboratory award and the National Institutes of Health. TRANSLATIONS: For the French and Lingala translations of the abstract see Supplementary Materials section.
引用
- Thompson P, Morgan CE, Ngimbi P, et al. Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study. Lancet Glob Health. 2021. PMID: 34416175. doi:10.1016/S2214-109X(21)00304-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。